Maintaining BP clinically and economically vital in OA

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.472, 2005-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Modest BP changes greatly affect CV risk, cost burden in OA, RA

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 411, 2003-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Celecoxib brings relief in OA

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 246, 2000-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Novel Therapies in OA

Current Drug Targets, Vol. 11, Iss. 5, 2010-05 ,pp. : 614-619

Bentham Science Publishers

Access to resources Recommend Favorite

Celecoxib: a model therapy for RA and OA

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 277, 2000-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite

Cost of OA varies with definition criteria

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 389, 2002-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite